MassMutual Private Wealth & Trust FSB Takes $40,000 Position in 23andMe Holding Co. (NASDAQ:ME)

MassMutual Private Wealth & Trust FSB purchased a new position in 23andMe Holding Co. (NASDAQ:ME) during the fourth quarter, Holdings Channel reports. The firm purchased 12,300 shares of the company’s stock, valued at approximately $40,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. FNY Investment Advisers LLC bought a new stake in 23andMe during the fourth quarter worth $26,000. Geode Capital Management LLC raised its holdings in shares of 23andMe by 0.7% during the 3rd quarter. Geode Capital Management LLC now owns 4,246,093 shares of the company’s stock worth $1,476,000 after buying an additional 28,252 shares in the last quarter. Vanguard Personalized Indexing Management LLC lifted its position in shares of 23andMe by 410.4% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 88,555 shares of the company’s stock worth $35,000 after buying an additional 71,204 shares during the last quarter. Point72 DIFC Ltd acquired a new stake in 23andMe in the second quarter valued at about $43,000. Finally, FMR LLC grew its position in 23andMe by 24.0% in the third quarter. FMR LLC now owns 993,848 shares of the company’s stock valued at $345,000 after acquiring an additional 192,099 shares during the last quarter. Institutional investors and hedge funds own 36.10% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of 23andMe in a research note on Saturday, January 18th.

23andMe Stock Performance

Shares of NASDAQ:ME opened at $3.50 on Friday. 23andMe Holding Co. has a 52-week low of $2.65 and a 52-week high of $16.52. The company has a market capitalization of $91.42 million, a PE ratio of -0.14 and a beta of 1.14. The company has a fifty day moving average of $3.45 and a 200-day moving average of $5.50.

23andMe (NASDAQ:ME) last issued its earnings results on Tuesday, November 12th. The company reported ($2.32) earnings per share (EPS) for the quarter. 23andMe had a negative return on equity of 129.98% and a negative net margin of 318.39%. The firm had revenue of $44.07 million during the quarter, compared to analyst estimates of $50.30 million.

23andMe Company Profile

23andMe Holding Co operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications.